



GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030
 CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 2495 9494

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2022

(Rs. in Lakhs)

	Particulars	3 months ended 30.06.2022	Preceding 3 months ended 31.03.2022	Corresponding 3 months ended 30.06.2021	Year ended 31.03.2022
		(Unaudited)	(Unaudited) (Refer Note 3)	(Unaudited)	(Audited)
	Continuing operations				
	Income				
1	Revenue from operations	72946	79192	70184	321751
2	Other income (Refer Note 4)	2779	1894	3173	7622
3	Total Income (1+2)	75725	81086	73357	329373
	Expenses				
	(a) Cost of materials consumed	13814	13315	16714	55247
	(b) Purchases of stock-in-trade	27160	18410	12691	72944
	(c) Changes in Inventories of finished goods, stock-in-trade and work-in-progress	(13686)	1835	(1326)	1383
	(d) Employee benefits expense	15122	14004	16779	61023
	(e) Finance costs	68	27	79	199
	(f) Depreciation and amortisation expense	1582	1535	1754	6819
	(g) Other expenses	15743	14286	12152	55571
4	Total expenses	59803	63412	58843	253186
5	Profit before exceptional items and tax (3-4)	15922	17674	14514	76187
6	Exceptional items [net] (Refer Note 5)	-	2950	-	1158
7	Profit before tax (5+6)	15922	20624	14514	77345
8	Tax expense				
	(a) Current tax	4706	5764	4202	21943
	(b) Deferred tax	(347)	247	(348)	(1050)
	(c) Tax adjustment of earlier years (Refer Note 6)	-	20200	-	18794
9	Profit for the period/year from continuing operations (7-8)	11563	(5587)	10660	37658
	Discontinued operations				
10	Profit before tax from discontinued operations (Refer Note 7)	413	165225	1879	170818
11	Tax expense of discontinued operations (Refer Note 7)	108	37854	499	39423
12	Profit from discontinued operations after taxes (10-11)	305	127371	1380	131395
13	Profit for the period (9+12)	11868	121784	12040	169053



GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030
 CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 2495 9494

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2022


(Rs. in Lakhs)

	Particulars	3 months ended 30.06.2022	Preceding 3 months ended 31.03.2022	Corresponding 3 months ended 30.06.2021	Year ended 31.03.2022
		(Unaudited)	(Unaudited) (Refer Note 3)	(Unaudited)	(Audited)
14	Other comprehensive income				
	(i) Items that will not be reclassified to profit or loss	-	(247)	-	(247)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	62	-	62
15	Total comprehensive income for the period (13+14)	11868	121599	12040	168868
	Paid-up equity share capital (face value per share Rs. 10)	16941	16941	16941	16941
	Other equity				250821
	Earnings per share (EPS)				
	Earnings per share (EPS) (of Rs. 10 each) (for continuing operations)				
	Basic and diluted EPS before Exceptional items (Rs.)	6.83	(4.64)	6.29	21.48
	Basic and diluted EPS after Exceptional items (Rs.)	6.83	(3.30)	6.29	22.23
	Earnings per share (EPS) (of Rs. 10 each) (for discontinued operations)				
	Basic and diluted EPS for discontinued operations (Rs.)	0.18	75.19	0.81	77.56
	Earnings per share (EPS) (of Rs. 10 each) (for continuing and discontinued operations)				
	Basic and diluted EPS before Exceptional items (Rs.)	7.01	70.55	7.11	99.05
	Basic and diluted EPS after Exceptional items (Rs.)	7.01	71.89	7.11	99.79
		Not Annualised			

Notes:

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 25th July 2022.
 2. In accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Statutory Auditors have carried out a limited review of the standalone financial results for the quarter ended 30th June, 2022.
 3. The figures for the 3 months ended 31st March 2022 are the balancing figures between the audited figures in respect of full financial year and the published year to date figures upto the third quarter of the financial year ended 31st March, 2022.
 4. Other income includes interest on income tax refund for the quarter ended 30th June 2021 Rs. 2121 Lakhs and for the year ended 31st March 2022 Rs. 2684 lakhs.
 5. Exceptional items for the year ended 31st March 2022 of Rs.1158 Lakhs comprise of:
 - a) Profit on sale of Property Rs. 3140 lakhs
 - b) Additional charge of Rs. 2008 lakhs on account of restructuring of the commercial functions.
 - c) Credit of Rs. 170 lakhs from post-transaction closing adjustments consequent to disposal of Asset held for sale at Vemgal.
 - d) Other charges of Rs. 144 lakhs
- Exceptional items for the quarter ended 31st March 2022 of Rs.2950 Lakhs comprise of:
- a) Profit on sale of Property Rs. 2950 lakhs
6. Tax provision in respect of earlier years includes provisions (including interest) amounting to Rs. 20200 lakhs towards possible disallowances of expenses incurred in prior years towards certain promotional spends which are under litigation with the authorities.
 7. The Board of Directors ('Board') of the Company during the previous year had approved the transfer of the trademarks pertaining to 'Iodex' and 'Ostocalcium' brands (" Brands") in India along with legal, economic, commercial and marketing rights of such brands and other identified assets to GlaxoSmithKline Asia Private Limited with respective values aggregating Rs. 1649,01 lakhs. The transaction was consummated and the consideration was received by the company during the quarter ended 31st March 2022 after the receipt of shareholders' and regulatory approvals. Consequently, the profits arising from transfer of brands and sale of products as per the terms of contract has been disclosed as Discontinued Operations in accordance with Ind AS 105 "Non-Current Assets Held for Sale and Discontinued Operations". The previous periods have been restated to give effect to the presentation requirements of Ind AS 105.
 8. The Company has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made.
 9. Previous periods' figures have been re-grouped / re-classified wherever necessary.

25th July, 2022


By Order of the Board

Sridhar Venkatesh
Managing Director
DIN: 07263117

